ST. LOUIS — Canopy BiosciencesTM, LLC, a leading provider of gene editing and personalized medicine technologies, announced today that it has launched two novel services for immuno-oncology and neurodegenerative disease. Both services allow researchers to assess the expression of nearly 800 disease-relevant genes in a single sample. The new Neuropathology service allows researchers to conduct […]
Canopy Biosciences launches CRISPR Complete Gene Editing Kits.
Canopy Biosciences signs deal with Array Bridge to market kits for impurity analysis.